- Home
- CXAI vs ACXP Comparison
CXAI vs ACXP Comparison
Compare CXAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXAI | ACXP |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 6.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CXAI | ACXP |
|---|---|---|
| Price | $0.40 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | ★ 2.7M | 79.9K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,222,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $3.17 |
| 52 Week High | $2.54 | $25.00 |
Technical Indicators
Market Signals| Indicator | CXAI | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 46.95 |
| Support Level | $0.36 | $3.98 |
| Resistance Level | $0.60 | $4.36 |
| Average True Range (ATR) | 0.06 | 0.39 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 16.53 | 62.89 |
Price Performance
Historical ComparisonAbout CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.